Sunday, April 30, 2023, Chicago, Illinois, 6:00 PM – 8:00 PM Central Time (7:00 PM – 9:00 PM Eastern Time)

Beyond The Guidelines: Urologic Oncology Investigators Provide Perspectives on the Optimal Management of Prostate Cancer

Part 2 of a 2-Part CME Satellite Symposium Series Held in Conjunction with the American Urological Association Annual Meeting 2023 (AUA2023)

Location
McCormick Place Convention Center
2301 South Martin Luther King Drive
Chicago, IL 60616
Phone: (312) 791-7000

Program Schedule — Central Time
5:30 PM – 6:00 PM — Registration and Dinner
6:00 PM – 8:00 PM — Educational Meeting

Meeting Room
Grand Ballroom (S100) — Level 1, South Building


This event will also be webcast live.
Please see Registration tab for details.
There is no registration fee for this event. For the in-person symposium in Chicago, preregistration is required as seating is limited.  
 
Faculty
Himisha Beltran, MD
Associate Professor of Medicine
Lank Center for Genitourinary Oncology and
the Division of Molecular and Cellular Oncology
Director of Translational Research, Medical Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Stephen J Freedland, MD
Staff Physician, Durham VA Medical Center
Durham, North Carolina
Professor of Urology
Warschaw, Robertson, Law Families Chair
in Prostate Cancer
Director, Center for Integrated Research on Cancer and Lifestyle (CIRCL)
Associate Director for Education and Training
Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, California


Fred Saad, MD
Professor and Chief of Urology
Director of GU Oncology
Raymond Garneau Chair in Prostate Cancer
University of Montreal Hospital Center (CHUM)
Director, Prostate Cancer Research
Montreal Cancer Institute/CRCHUM
Montréal, Québec, Canada

Neal D Shore, MD
Director, CPI
Carolina Urologic Research Center
Chief Medical Officer, Surgery/Urology
GenesisCare
Medical Director, CUSP: Clinical Research Consortium
Myrtle Beach, South Carolina

Moderator
Matthew R Smith, MD, PhD
Claire and John Bertucci Endowed Chair
in Genitourinary Cancers
Professor of Medicine
Harvard Medical School
Director, Genitourinary Malignancies Program
Massachusetts General Hospital Cancer Center
Boston, Massachusetts


This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, and Merck.
Program Schedule — Central Time
5:30 PM – 6:00 PM — Registration and Dinner Buffet
6:00 PM – 8:00 PM — Educational Meeting

MODULE 1: Management Approaches for Nonmetastatic Prostate Cancer — Dr Freedland

  • Indications for and selection of androgen deprivation therapy (ADT) for patients with prostate cancer
  • Key data with and FDA-approved indications for relugolix
  • Findings from the STAMPEDE trial of abiraterone and prednisolone with or without enzalutamide in combination with ADT for men with high-risk nonmetastatic prostate cancer
  • Key findings from the Phase III PRESTO study evaluating ADT intensification with apalutamide with or without abiraterone for patients with biochemically recurrent prostate cancer and a rapid PSA doubling time
  • Design, eligibility criteria and emerging efficacy and safety findings from the Phase III EMBARK trial evaluating enzalutamide alone or with leuprolide for patients with nonmetastatic prostate cancer and high-risk biochemical recurrence
  • Long-term findings with apalutamide, enzalutamide or darolutamide for patients with nonmetastatic castration-resistant prostate cancer (CRPC)
  • Factors guiding the selection of enzalutamide, apalutamide or darolutamide for patients with nonmetastatic CRPC

MODULE 2: Optimizing the Care of Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) — Dr Saad

  • Key factors in the selection of systemic therapy for patients with mHSPC
  • Long-term data with docetaxel, abiraterone, enzalutamide and apalutamide, each in combination with ADT, for mHSPCC
  • Major findings from the Phase III PEACE-1 study of ADT and docetaxel, with or without local radiation therapy, with or without abiraterone and prednisone for mHSPC
  • Published results from the Phase III ARASENS trial of darolutamide with docetaxel and ADT for mHSPC; FDA-approved indication and optimal incorporation into management algorithms
  • Ongoing Phase III trials attempting to further define the optimal management of mHSPC (eg, TALAPRO-3, CYCLONE 3, PSMAddition, CAPItello-281)

MODULE 3: Therapeutic Considerations for Patients with Newly Diagnosed Metastatic CRPC (mCRPC) — Dr Shore

  • Key factors in the selection of therapy for patients with newly diagnosed mCRPC; impact of earlier use of chemotherapy and secondary hormonal therapy on current treatment algorithms
  • Key findings from clinical trial and real-world data sets exploring the efficacy and safety of sipuleucel-T for mCRPC; effect on outcomes of patient age, race, PSA level and other factors
  • Biologic basis for combining PARP inhibitors with antiandrogen therapies for prostate cancer; rationalefor the activity of these combinations as front-line therapy in patients without homologous recombination repair (HRR) gene mutations
  • Available data with PARP inhibitors in combination with secondary hormonal therapies in previously untreated mCRPC from the Phase III PROpel, MAGNITUDE and TALAPRO-2 studies
  • Biologic rationale for the evaluation of CDK4/6 inhibitors in patients with mCRPC
  • Design, eligibility criteria and primary and secondary endpoints of the Phase II/III CYCLONE 2 trial evaluating first-line abiraterone and prednisone with or without abemaciclib for mCRPC

MODULE 4: Contemporary Management of mCRPC in Patients Harboring an HRR Gene Alteration — Dr Smith

  • Incidence and clinical implications of BRCA1/2 and other HRR abnormalities among patients with prostate cancer
  • Mechanistic similarities and differences between approved and investigational PARP inhibitors with documented activity in patients with mCRPC
  • Available data with PARP inhibitor monotherapy for patients with mCRPC
  • FDA-approved indications for olaparib and rucaparib for mCRPC and optimal integration into management algorithms
  • Key findings among patients with HRR gene alterationsfrom the Phase III PROpel, MAGNITUDE and TALAPRO-2 trials; ramifications for current and future practice

MODULE 5: Current and Emerging Strategies in the Treatment of Recurrent mCRPC — Dr Beltran

  • Available data with, ongoing evaluation of and patient selection for treatment with radium-223 chloride
  • Clinical relevance of PSMA expression in prostate cancer; mechanism of action of the novel radioligand therapy lutetium Lu 177 vipivotide tetraxetan
  • Published (eg, VISION) and emerging (eg, PSMAfore) data sets informing the use of lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mCRPC; appropriate integration into clinical practice
  • Major findings from the CARD study and other recently reported trials investigating cabazitaxel for mCRPC; appropriate integration into the treatment algorithm and practical considerations with its use
  • Other promising novel agents and strategies under investigation for mCRPC (eg, capivasertib, ODM-208, cabozantinib/atezolizumab)

Target Audience
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.

Learning Objectives
Upon completion of this activity, participants should be able to

  • Appraise published and emerging research findings and current guideline recommendations on optimal management approaches for biochemical recurrence after local treatment for prostate cancer, and appropriately counsel patients about the potential benefits of systemic therapy.
  • Evaluate the research supporting the FDA approvals of secondary hormonal agents in the management of nonmetastatic castration-resistant prostate cancer (CRPC), and present appropriate nonresearch treatment options to patients.
  • Explore available data with treatment intensification using cytotoxic therapy, secondary hormonal therapy or combinations of both for metastatic hormone-sensitive prostate cancer, and effectively integrate these strategies into clinical management algorithms.
  • Establish an evidence-based approach to the selection and sequencing of therapies for patients with metastatic CRPC (mCRPC), considering age, comorbidities, prior therapeutic exposure and other clinical and biologic factors.
  • Assess available research with PARP inhibitors as monotherapy for patients with mCRPC harboring a homologous recombination repair (HRR) gene alteration, and discern how to optimally incorporate these agents into clinical management algorithms.
  • Understand the rationale for, available data with and ongoing research evaluating PARP inhibitors with androgen receptor-targeted therapy, and consider the potential role of these novel regimens in therapy for patients both with and without HRR gene mutations.
  • Recall the design of ongoing clinical trials evaluating other novel agents and strategies for prostate cancer, and appropriately counsel patients about availability and participation.

CME Credit Form
A CME credit link will be given to each participant at the conclusion of the activity.

Accreditation Statement
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Content Validation and Disclosures
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest will have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

FACULTY — The following faculty reported relevant financial relationships with ineligible entities:

Dr Beltran — Advisory Committee: Amgen Inc, Bayer HealthCare Pharmaceuticals, Blue Earth Diagnostics, Curie Therapeutics, Daiichi Sankyo Inc, Foundation Medicine, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, Merck, Oncorus, Pfizer Inc, Sanofi; Contracted Research: Bristol-Myers Squibb Company, Circle Pharma, Daiichi Sankyo Inc, Novartis; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP. Dr Freedland — Consulting Agreements: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Merck, Myovant Sciences, Pfizer Inc, Sanofi; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Sanofi. Dr Saad — Consultant: AbbVie Inc, Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Merck, Myovant Sciences, Novartis, Pfizer Inc, Tolmar; Grant/Research Support (Institution): Advanced Accelerator Applications, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Exelixis Inc, Janssen Biotech Inc, Merck, Novartis, Pfizer Inc, Sanofi. Dr Shore — Consulting Agreements: AbbVie Inc, AIkido Pharma Inc, Alessa Therapeutics, Amgen Inc, Arquer Diagnostics, Asieris Pharmaceuticals, Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Boston Scientific Corporation, Bristol-Myers Squibb Company, CG Oncology, Clarity Pharmaceuticals, Clovis Oncology, Dendreon Pharmaceuticals Inc, Exact Imaging, Exact Sciences Corporation, FerGene, Ferring Pharmaceuticals, FIZE Medical, Foundation Medicine, Genentech, a member of the Roche Group, GenesisCare, Guardant Health, ImmunityBio, Incyte Corporation, Invitae, Janssen Biotech Inc, Lantheus, Lilly, MDxHealth, Merck, Minomic, Myovant Sciences, Myriad Genetic Laboratories Inc, NGM Biopharmaceuticals, Nonagen Bioscience, Novartis, Nymox Pharmaceutical Corporation, Pacific Edge, Pfizer Inc, Photocure, PlatformQ, ProFound Therapeutics, Promaxo, Propella Therapeutics Inc, Protara Therapeutics, Sanofi, Sesen Bio, Specialty Networks, Telix Pharmaceuticals Limited, Tolmar, UroGen Pharma, Vaxiion Therapeutics, Vessi Medical; Contracted Research: Astellas, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Candel Therapeutics, CG Oncology, Dendreon Pharmaceuticals Inc, DisperSol Technologies LLC, Eric Pharmaceuticals, Exact Imaging, Exelixis Inc, FKD Therapeutics Oy, Forma Therapeutics, Genentech, a member of the Roche Group, Guardant Health, Janssen Biotech Inc, Jiangsu Yahong Meditech, Johnson & Johnson Pharmaceuticals, Medivation Inc, a Pfizer Company, Merck Sharp & Dohme LLC, MT Group, Myovant Sciences, Novartis, OncoCellMDx, Pacific Edge, Palette Life Sciences, Pfizer Inc, Plexxikon Inc, POINT Biopharma, Propella Therapeutics Inc, RhoVac ApS, Seagen Inc, STEBA Biotech NV, Theralase Technologies Inc, UroGen Pharma, Urotronic, US Biotest Inc, Vaxiion Therapeutics, Veru Inc, Zenflow.

MODERATOR — Matthew R Smith, MD, PhD – Advisory Committee and Consulting Agreements: Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc; Contracted Research (to Institution): Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, Lilly, Pfizer Inc.

RESEARCH TO PRACTICE PRESIDENT NEIL LOVE, MD — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.

RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.

Supporters
This activity is supported by educational grants from Astellas and Pfizer Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Lilly, and Merck.

McCormick Place Convention Center
2301 South Martin Luther King Drive
Chicago, IL 60616
Phone: (312) 791-7000

Meeting Room
Grand Ballroom (S100) – Level 1, South Building

Directions
The McCormick Place Convention Center is the main venue for the 2023 AUA Annual Meeting.

 
This activity has been designed to meet the educational needs of medical and radiation oncologists, urologists and other allied healthcare professionals involved in the treatment of prostate cancer.

​ ​ ​
IN-PERSON registration
Thank you for your interest in our CME program. At this time online preregistration for in-person is closed for this event. SEATS ARE STILL AVAILABLE FOR THE SESSION. Our Onsite Registration Desk will be open at 5:30 PM Central Time on Sunday, April 30th. If you are interested in attending, please visit our onsite registration desk outside the Grand Ballroom (S100) — Level 1, South Building at the McCormick Place Convention Center where the AUA Annual Meeting is taking place. Please note: Seats will be offered on a first come, first served basis, and onsite registration does not guarantee participation in the meal service.

If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com, or call (800) 233-6153.

NOTICE:
Registration for this event is independent of registration for the 2023 AUA Annual Meeting.

LIVE WEBCAST registration for all professionals

Please note we will stream this event over Zoom. After registering you will receive a separate confirmation from Zoom with the viewing instructions.

REGISTRATION FOR WEBCAST »

Registration for groups
If you are registering a group (more than 1 person) for this event, please contact us at Meetings@ResearchToPractice.com or (800) 233-6153.
To ensure seating and meal service, please check in at our onsite registration desk at least 30 minutes before the start of the meeting. We cannot guarantee seating after the start of the program.

Photography and/or video recording may be taken during the educational program by Research To Practice and used in future educational offerings.

Research To Practice fully complies with the legal requirements of the ADA. If you are in need of assistance (ie, physical, dietary, et cetera), please contact us prior to the event at (800) 233-6153.